Skip to main content

Follow us

Home

Search

the Gateway to Research in Oklahoma

  • Researchers
  • Providers
  • Patients
  • About GRO

Gateway to Research in Oklahoma


Oklahoma Shared Clinical and Translational Resources U54 GM104938

Researchers

imgResearchers

The GRO: Researcher Portal provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in Oklahoma.

Providers

imgProviders

The GRO: Provider Portal assists medical providers to identify clinical research opportunities in Oklahoma, tools for patient education, and evidence-based resources to improve patient care.

Patients

imgPatients

The GRO: Patient Portal can help patients and families to learn more about clinical and translational research and to connect with opportunities to participate in research opportunities in your communities.

Oklahoma Research Highlights

The Effect of Heparinization Practices on the Incidence of Deep Vein Thrombosis in Pediatric Ablations

2 months 1 week ago
No abstract
Ganesh Prasanna

A Prospective Study Characterizing Cognitive Function in Patients with Inflammatory Bowel Disease

2 months 1 week ago
INTRODUCTION: Inflammatory bowel disease (IBD) may be associated with cognitive impairment. Cognitive decline is also linked to weaker anesthesia-induced alpha wave electroencephalographic (EEG) signals. We aimed to characterize the associations between cognition and EEG alpha power in patients with IBD.
Praachi Raje

The Impact of Pain Coping Strategies on Chronic Pain Among Native Americans

2 months 1 week ago
No abstract
Taylor V Brown

Arbuscular mycorrhizal symbiosis enhances the cadmium stress tolerance of Medicago sativa in association with regulation of the aminolevulinic acid pathway

2 months 1 week ago
No abstract
Yajing Li

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer

2 months 1 week ago
The combination of avutometinib (a rapidly accelerated fibrosarcoma/mitogen-activated protein kinase kinase [RAF/MEK] inhibitor) and defactinib (a focal adhesion kinase [FAK] inhibitor) demonstrated meaningful efficacy and tolerability in recurrent KRAS-mutated low-grade serous ovarian carcinoma, as evidenced by clinically meaningful response rates and manageable adverse events. Avutometinib plus defactinib is a new, individualized treatment option for recurrent KRAS-mutated low-grade serous...
Sarah Hayward

Pagination

  • Previous page ‹ Previous
  • Page 84
  • Next page Next ›
Subscribe to

octsi logo

1000 N. Lincoln Blvd, Suite 2100, Oklahoma City, OK 73104
Copyright © 2021 The Board of Regents of the University of Oklahoma, All Rights Reserved.

About GRO

News
Publications
FAQ

Terms of Use

Privacy Policy
Accessibility

Contact

info email
info phone
Copyright © 2026. All rights reserved. Designed By Zymphonies